A Comparative Study Of Outcome Of Acute Pancreatitis With Combination Of Ulinastatin And Octreotide And With Only Octreotide

Abstract

An acute inflammatory process of the pancreas from mild interstitial to severe pancreatitis with pancreatic necrosis and concomitant multi-organ failure is defined as Acute Pancreatitis (AP). Over the centuries the pathogenesis has been investigated, which varies across population. Several factors including gallstones, alcohol, trauma, infections and hereditary factors lead to Acute Pancreatitis. The onset is rapid and quickly diagnosed.

The aim of this prospective randomized controlled trial was to assess whether octreotide reduces the elevated serum levels of amylase and lipase in patients admitted with diagnosis of Acute Pancreatitis.           

A comparative analysis of administration of injection octreotide and injection Ulinastatin for 5 days as Group A and administration of injection octreotide and fluids alone as Group B was done based on outcome of severity of disease reduction on biochemical markers and radiological changes after administration of drugs. Biochemical parameters like CRP, TLC, AST, and ALT was found to be elevated. The CTSI score was taken on day 1 and day 10 respectively indicates ulinastatin & octreotide had better improvement when compared with Octreotide group B.

The combination of octreotide with ulinastatin treatment has short term effect for AP patients, which improved the treatment efficiency, shorten the time for symptom improvement and the drug safety is relatively high, which is worthy of promotion and application. The results of this study provides comprehensive assessment on the efficacy and safety of octreotide combined with ulinastatin for treating patients with Severe Acute Pancreatitis (SAP), and is an evidence for the clinical practice and future studies.